Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) from Vatel Capital SAS, Nyenburgh Investment Partners, BIO JAG and Greenstock for ?99.1 million on June 19, 2023. Under the terms, ?35 per share in cash will be paid. Acquisition is subject to subject to customary regulatory approvals. As of September 8, 2023. The AMF announces that the simplified public purchase offer filed on Biocorp shares by Portzamparc and Lazard Frères Banque, acting on behalf of Novo Nordisk, will be opened from September 7, 2023 to September 27, 2023. Stifel acted as financial advisor and McDermott Will & Emery acting as legal advisor to Biocorp. Lazard acted as financial advisor and Bird & Bird acting as legal advisor to Novo Nordisk.

Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) from Vatel Capital SAS, Nyenburgh Investment Partners, BIO JAG and Greenstock on August 4, 2023.